BioSpace News Archive

ProQR Prices Approximately $20M Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

In addition, in the public offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares at the public offering price, less underwriting discounts and commissions.

November 14, 2017

·

4 min read

Business

Veloxis Pharma Announces Financial Results for the First Nine Months of 2017

Veloxis reported a net loss of tUSD 8,421 for the first nine months of 2017 compared to a net loss of tUSD 23,961 for the same period in 2016.

November 14, 2017

·

2 min read

Drug Development

Neurocrine Announces Long-Term Results Evaluating INGREZZA for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry

The once-daily 80 mg and 40 mg doses of INGREZZA continued to maintain symptom improvement and were generally well-tolerated over long-term dosing in patients with TD, a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face.

November 14, 2017

·

7 min read

BioForest

BladderScan Prime Plus from Verathon Takes Accuracy and Ease of Use to a New Level

Powered by ImageSenseartificial intelligence (AI), BladderScan Prime Plus provides exceptional accuracy with enhanced, “point and click” ease of use.

November 14, 2017

·

3 min read

Business

Breathtec Biomedical Unaware of Any Material Change

The Company will continue to provide updates of any material changes if and when they occur.

November 14, 2017

·

2 min read

Business

TearLab Corporation Reports Third Quarter and September Year-To-Date 2017 Financial Results

For the three months ended September 30, 2017, TearLab’s net revenues were $6.5 million, compared with $7.2 million for the same period in 2016.

November 14, 2017

·

8 min read

Business

Cloud Technology Veteran, Lili Nader, Named CTO of Riffyn

Ms. Nader is a co-founder of Riffyn and served as the chief software architect of Riffyn’s cloud-based SDE since 2014.

November 14, 2017

·

2 min read

Business

Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results

The Company reported a net loss of $2.2 million or $0.12 per diluted share for quarter ended September 30, 2017 compared to a net loss of $2.3 million or $0.19 per diluted share for the same period in 2016.

November 14, 2017

·

8 min read

Drug Development

Akcea Initiates AKCEA-ANGPTL3-LRx Phase II Program in Patients With Rare Hyperlipidemias

AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3, or ANGPTL3.

November 14, 2017

·

8 min read

Drug Development

TRACON Pharmaceuticals Announces Positive Results From Phase I Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget

Overall response rate of 24% seen with no dose limiting toxicity observed.

November 14, 2017

·

4 min read